For a study, researchers sought to assess clinical and patient-reported outcomes (PROs) 6 months after starting secukinumab in psoriatic arthritis (PsA) patients in the United States.

Patients with PsA in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry who started secukinumab between April 1, 2017, and December 2, 2019, and continued secukinumab at their 6-month follow-up appointment were included in the study. At 6 months, all patients who received secukinumab as a first-line biologic were assessed for minimum disease activity (MDA), remission (i.e., no evidence) of sore and swollen joint counts, enthesitis, and dactylitis, and change in disease activity and PROs.

Most of the 100 eligible patients (83.0%) had prior biologic experience, and 17.0% started secukinumab as a first-line biologic. After the start, 75/90 patients (83.3%) with accessible data were not in MDA; at 6 months, 26/71 (36.6%) with follow-up data achieved MDA. Furthermore, after 6 months, 28/68 patients (41.2%) with ≥1 sore joint, 24/54 (44.4%) with ≥1 swollen joint, 17/28 (60.7%) with enthesitis, and 9/12 (75.0%) with dactylitis had resolved. After 6 months, patients with PsA who started and continued secukinumab showed improvements in clinical symptoms, PRO measures, work productivity, and activity.

Patients with PsA who received and maintained secukinumab for 6 months obtained MDA in proportions commensurate with clinical trials and displayed improvements in clinical symptoms and PROs in this real-world population.